Clinical impact of positron emission tomography (PET) with (18F)fluorodeoxyglucose (FDG) in head and neck tumours

Acta Oto-Laryngologica

Volumn 127, Issue 2, 2007, Pages 186-193

  Ekberg, Tomas ^a   Sörensen, Jens ^a   Engström, Mats ^a   Blomquist, Erik ^a   Sundin, Anders ^a   Anniko, Matti ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

FDG; Head and neck; PET; Recurrence; Tumour

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; DRUG UPTAKE; FEMALE; FOLLOW UP; HEAD AND NECK TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; MOUTH TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33847200379     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480600801407     Document Type: Article

References (24)

1. Greven KM. Positron-emission tomography for head and neck cancer. Semin Radiat Oncol 2004;14:121-9.
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
3. Kubota K, Yamada K, Yoshioka S, Yamada S, Ito M, Ido T. Differential diagnosis of idiopathic fibrosis from malignant lymphadenopathy with PET and F-18 fluorodeoxyglucose. Clin Nucl Med 1992;17:361-3.
4. Hannah A, Scott AM, Tochon-Danguy H, Chan JG, Akhurst T, Berlangieri S, et al. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002;236:208-17.
5. Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816-22.
6. Regelink G, Brouwer J, de Bree R, Pruim J, van der Laan BF, Vaalburg W, et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging 2002;29:1024-30.
7. Wong WL, Saunders M. The impact of FDG PET on the management of occult primary head and neck tumours. Clin Oncol (R Coll Radiol) 2003;15:461-6.
8. Schoder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 2004;34:180-97.
9. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-43.
10. Hollenbeak CS, Lowe VJ, Stack BC Jr. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. Cancer 2001;92:2341-8.
11. Ng SH, Joseph CT, Chan SC, Ko SF, Wang HM, Liao CT, et al. Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med 2004;45:1669-76.
12. Sigg MB, Steinert H, Gratz K, Hugenin P, Stoeckli S, Eyrich GK. Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities. J Oral Maxillofac Surg 2003;61:1022-9.
13. Borjesson PK, Postema EJ, de Bree R, Roos JC, Leemans CR, Kairemo KJ, et al. Radioimmunodetection and radioimmunotherapy of head and neck cancer. Oral Oncol 2004;40:761-72.
14. Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A, et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem 2004;12:3421-9.
15. Verel I, Visser GW, Vosjan MJ, Finn R, Boellaard R, van Dongen GA. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging 2004;31:1645-52.
16. Bui CD, Ching AS, Carlos RC, Shreve PD, Mukherji SK. Diagnostic accuracy of 2-[fluorine-18]fluro-2-deoxy-D-glucose positron emission tomography imaging in nonsquamous tumors of the head and neck. Invest Radiol 2003;38:593-601.
17. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994;73:187-90.
18. Jones AS, Roland NJ, Field JK, Phillips DE. The level of cervical lymph node metastases: their prognostic relevance and relationship with head and neck squamous carcinoma primary sites. Clin Otolaryngol 1994;19:63-9.
19. McGuirt WF, Matthews B, Koufman JA. Multiple simultaneous tumors in patients with head and neck cancer: a prospective, sequential panendoscopic study. Cancer 1982;50:1195-9.
20. Ware RE, Matthews JP, Hicks RJ, Porceddu S, Hogg A, Rischin D, et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck 2004;26:1008-17.
21. Goerres GW, Schmid DT, Bandhauer F, Huguenin PU, von Schulthess GK, Schmid S, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004;130:105-9; discussion 120-1.
22. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836-9.
23. Schmidt M, Schmalenbach M, Jungehulsing M, Theissen P, Dietlein M, Schroder U, et al. 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis. Nuklearmedizin 2004;43:91-101; quiz 102-4.
24. Lapela M, Eigtved A, Jyrkkio S, Grenman R, Kurki T, Lindholm P, et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000;36:858-67.